The following important updates have been made to BMJ Best Practice topics.
NICE recommends teplizumab to delay progression to stage 3 type 1 diabetes
Topic: Type 1 diabetes, Section: Management: emerging
The National Institute for Health and Care Excellence (NICE) in the UK now recommends teplizumab as an option for delaying the onset of stage 3 type 1 diabetes in adults and children aged 8 years and over with stage 2 type 1 diabetes. Previously, there were no treatments available to delay progression to stage 3 disease, and management was limited to monitoring, education, and psychosocial support.
The National Institute for Health and Care Excellence (NICE) in the UK now recommends teplizumab as an option for delaying the onset of stage 3 type 1 diabetes in adults and children aged 8 years and over with stage 2 type 1 diabetes. Previously, there were no treatments available to delay progression to stage 3 disease, and management was limited to monitoring, education, and psychosocial support.
European guidance lowers the bar for starting antiviral therapy in chronic HBV
Topic: Hepatitis B, Section: Management: approach
The European Association for the Study of the Liver (EASL) has published its updated clinical practice guideline on the management of hepatitis B virus (HBV) infection. Recommendations for when to start antiviral therapy have been updated to make sure patients who may benefit from antiviral therapy are not left untreated.
The European Association for the Study of the Liver (EASL) has published its updated clinical practice guideline on the management of hepatitis B virus (HBV) infection. Recommendations for when to start antiviral therapy have been updated to make sure patients who may benefit from antiviral therapy are not left untreated.
Access BMJ Best Practice
BMJ Best Practice is available to all NHS staff via NHS OpenAthens username / password. Please see our BMJ Best Practice help page for more assistance using this essential resource.
Comments
Post a Comment